Ingelheim, GermanyApproval is based on results from Phase III FIBRONEER™-IPF trial, which showed statistically significant improvements in the ...

Two doses of 52-week nerandomilast reduced FVC decline vs. placebo in the subgroup of U.S. adults with idiopathic pulmonary ...

For U.S. patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slows the decline in forced vital capacity (FVC), ...

Tvardi Therapeutics has failed its first big test as a public company. | Tvardi Therapeutics has failed its first big test as a public company. Months after joining Nasdaq, the biotech has reported ...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today ...

The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis ...

"Boehringer’s Jascayd nets first FDA IPF approval in over 10 years" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

PureTech Health (PRTC) announced the presentation of new analyses from the Phase 2b ELEVATE IPF trial of deupirfenidone for the treatment of ...

Avalyn will present four posters in conjunction with the PFF Summit 2025 Welcome Reception from 5-8 p.m. CT on Thursday, November 13, 2025.

Tvardi Therapeutics recently announced preliminary results from its Phase 2 REVERT trial in idiopathic pulmonary fibrosis, revealing that TTI-101 did not show a significant difference in efficacy ...